Recruiting

Phase 1

Phase 2

CJH1A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

Sponsor:

Alexandra Marine and General Hospital

Code:

NCT01684475

Conditions

Parkinson's Disease

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Interventions

CJH1 (CLR4001)

Study Details

Brief summary:

The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.

Conditions

Parkinson's Disease

Study ID

NCT01684475

Start date

Sep, 2012

Status verified date

Sep, 2012

Completion date

Sep, 2013

Anticipated

Primary completion date

Sep, 2013

Eligibility Criteria

Sex: All

Age: 40 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patient's with Parkinson's disease

Exclusion Criteria:

Contraindications to study medication

Study Design

Enrollment

21 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment with CJH1

Interventions

CJH1 (CLR4001)

Primary outcome measure

Reduced signs and symptoms of Parkinson's disease [ Time Frame: 8 weeks ]

Central Contacts and Locations

Locations

Gateway Rural Health Research

Recruiting

Goderich, Ontario, Canada, N7A 1W5

Contacts

Craig Hudson, MD

519-524-8323

Principal Investigator:

Craig J Hudson, MD

More Information

Sponsor

Alexandra Marine and General Hospital

Last update posted

Sep 13, 2012

Last verified

Sep, 2012

Keywords

Novel Treatment Parkinson's disease

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Alexandra Marine and General Hospital on 2012-09-13.